

Table of Contents and List of Tables



Over 1,000 corporations in 70 countries are relying on our market intelligence, expert analysis, and strategic insight, critical to the development and implementation of effective business, R&D and marketing programs.

www.LeadingMarketResearch.com

www.VPGMarketResearch.com

reports@vpgcorp.com

+1 212 564 2838

Table of Contents

I. Introduction

II. Worldwide Market Overview

III. Major Product Development Opportunities

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. Design Criteria for Decentralized Testing Products

V. Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

Table of Contents (continued)

B. Major Current and Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - CD44
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
 - PIK3CA
 - PTI-1
 - Ras
 - Reg

Table of Contents (continued)

- Sis
- Src and others
- 28. Polypeptide Growth Factors
 - Basic Fibroblast Growth Factor
 - Beta-TGF
 - Cachectin (TNT)
 - Calmodulin
 - ECFR
 - Nerve Growth Factor (NGF)
 - Epidermal Growth Factor (EGF)
 - Ornithine Decarboxylase
 - Transferrin
 - Transforming Growth Factor-Alpha
- 29. Ectopic Hormones
- 30. Colony Stimulating Factors
- 31. Lymphokines
 - Alpha-Interferon
 - B Cell Growth Factors
 - B Cell Growth Factor (BCGF)
 - Gamma-Interferon
 - Interleukin-1 (IL-1)
 - Macrophage Activating Factor
- 32. Immunohistochemical Stains
- 33. Emerging Tumor Markers
 - N-Acetylglucosamine
 - Actin
 - Alpha-Actin
 - Antineuronal Antibodies
 - 7B2
 - B72.3
 - Bax
 - BCD-F9
 - BLCA-4
 - Blood Group Antigens A,B,H
 - CA 50
 - CA 72-4/TAG-72
 - CA 195
 - CA-242
 - CA-549
 - CAM 26
 - CAR-3
 - Cathepsin-D
 - Chromogranin A and B
 - Cluster 1 Antigen
 - Cluster-5/5A Antigen
 - CTA
 - CU18
 - DR-70

Table of Contents (continued)

- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

Table of Contents (continued)

- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen and others

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

D. Current and Emerging Cancer Diagnostic Technologies

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies

E. Personal Testing

Table of Contents (continued)

VIII. 22-Country Market Analyses: Test Volume and Sales Forecasts, Supplier Shares

IX. Competitive Profiles

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

- Abbott
- Affymetrix
- Beckman Coulter/Danaher/Cepheid
- Becton Dickinson
- bioMerieux
- Bio-Rad
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujifilm Wako
- Fujirebio
- Grifols
- Hologic
- Leica Biosystems
- PerkinElmer
- Qiagen
- QuidelOrtho
- Roche
- Siemens Healthineers
- Takara Bio
- Thermo Fisher and others.

List of Tables

Argentina Cancer Diagnostic Volume Forecasts by Test

Argentina Cancer Diagnostics Sales Forecasts by Test

Bolivia Cancer Diagnostic Volume Forecasts by Test

Bolivia Cancer Diagnostics Sales Forecasts by Test

Brazil Cancer Diagnostic Volume Forecasts by Test

Brazil Cancer Diagnostics Sales Forecasts by Test

Chile Cancer Diagnostic Volume Forecasts by Test

Chile Cancer Diagnostics Sales Forecasts by Test

Colombia Cancer Diagnostic Volume Forecasts by Test

Colombia Cancer Diagnostics Sales Forecasts by Test

Costa Rica Cancer Diagnostic Volume Forecasts by Test

Costa Rica Cancer Diagnostics Sales Forecasts by Test

Cuba Cancer Diagnostic Volume Forecasts by Test

Cuba Cancer Diagnostics Sales Forecasts by Test

Dominican Republic Cancer Diagnostic Volume Forecasts by Test

Dominican Republic Cancer Diagnostics Sales Forecasts by Test

Ecuador Cancer Diagnostic Volume Forecasts by Test

Ecuador Cancer Diagnostics Sales Forecasts by Test

El Salvador Cancer Diagnostic Volume Forecasts by Test

El Salvador Cancer Diagnostics Sales Forecasts by Test

Guatemala Cancer Diagnostic Volume Forecasts by Test

Guatemala Cancer Diagnostics Sales Forecasts by Test

Haiti Cancer Diagnostic Volume Forecasts by Test

Haiti Cancer Diagnostics Sales Forecasts by Test

Honduras Cancer Diagnostic Volume Forecasts by Test

Honduras Cancer Diagnostics Sales Forecasts by Test

Jamaica Cancer Diagnostic Volume Forecasts by Test

Jamaica Cancer Diagnostics Sales Forecasts by Test

List of Tables

Mexico Cancer Diagnostic Volume Forecasts by Test

Mexico Cancer Diagnostics Sales Forecasts by Test

Nicaragua Cancer Diagnostic Volume Forecasts by Test

Nicaragua Cancer Diagnostics Sales Forecasts by Test

Panama Cancer Diagnostic Volume Forecasts by Test

Panama Cancer Diagnostics Sales Forecasts by Test

Paraguay Cancer Diagnostic Volume Forecasts by Test

Paraguay Cancer Diagnostics Sales Forecasts by Test

Peru Cancer Diagnostic Volume Forecasts by Test

Peru Cancer Diagnostics Sales Forecasts by Test

Puerto Rico Cancer Diagnostic Volume Forecasts by Test

Puerto Rico Cancer Diagnostics Sales Forecasts by Test

Uruguay Cancer Diagnostic Volume Forecasts by Test

Uruguay Cancer Diagnostics Sales Forecasts by Test

Venezuela Cancer Diagnostic Volume Forecasts by Test

Venezuela Cancer Diagnostics Sales Forecasts by Test

Tumor Marker Classification

Major Companies Developing or
Marketing ACTH Tests

Major Companies Developing or
Marketing AFP Tests

Major Companies Developing or
Marketing Beta-2 Microglobulin Tests

Major Companies Developing or
Marketing CA 15-3/27.29 Tests

Major Companies Developing or
Marketing CA 19-9 Tests

Major Companies Developing or
Marketing CA 125 Tests

List of Tables (continued)

Major Companies Developing or
Marketing Calcitonin Tests

Major Companies Developing or
Marketing CEA Tests

Major Companies Developing or
Marketing Estrogen Receptor Tests

Major Companies Developing or
Marketing Progesterone Receptor Tests

Major Companies Developing or
Marketing Ferritin Tests

Major Companies Developing or
Marketing Gastrin Tests

Major Companies Developing or
Marketing HCG Tests

Major Companies Developing or
Marketing Insulin Tests

Major Companies Developing or
Marketing NSE Tests

Major Companies Developing or
Marketing Occult Blood Tests

Major Companies Developing or
Marketing PAP Smear/HPV Tests

Major Companies Developing or
Marketing PAP Tests

Major Companies Developing or
Marketing PSA Tests

Major Companies Developing or Marketing
Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications
In Cancer Diagnosis

Oncogenes Potential Applications
In Cancer Diagnosis

List of Tables (continued)

Major Companies Developing or
Marketing Oncogene Tests

Growth Factors Potential Applications
In Cancer Diagnosis

Colony Stimulating Factors Potential
Applications in Cancer Diagnosis

Lymphokines Potential Applications
in Cancer Diagnosis

Immunohistochemical Stains Potential
Applications in Cancer Diagnosis